Testing a new PET scan for Nectin-4-positive tumors
Part of Cancer clinical trials.
This trial tests a new imaging injection (a radioactive tracer called 68Ga) that sticks to a protein called Nectin-4, which is often found on cancer cells. The goal is to see if this scan can better find tumors in people with certain solid cancers, such as bladder, breast, or lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your tumor has been confirmed to have high levels of Nectin-4 (a protein that the imaging test looks for).
- You have at least one tumor that can be seen on a scan (the original or a spread).
- You are healthy enough to be up and about (ECOG score 0–2) and expected to live at least 6 months.
- You have not had previous treatment that targets Nectin-4 (like Enfortumab vedotin).
- You are not pregnant, breastfeeding, or have other serious health conditions (like severe heart, liver, or kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
This study tests a new PET scan tracer that targets a protein called Nectin-4, which is found on some cancer cells. It aims to improve how doctors detect and monitor cancers like bladder, breast, and lung cancer. If you have one of these cancers, this scan might help your doctor see your cancer more clearly.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This trial tests an experimental drug (LNF2105) for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a protein called Nectin-4 on cancer cells, and participating could give you access to a new option while helping to evaluate its safety.
Hear when a new Solid Tumors With High Expression of Nectin4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.